The effects of atypical antipsychotic medications on psychosocial outcomes

被引:35
作者
Corrigan, PW [1 ]
Reinke, RR [1 ]
Landsberger, SA [1 ]
Charate, A [1 ]
Toombs, GA [1 ]
机构
[1] Univ Chicago, Ctr Psychiat Rehabil, Tinley Pk, IL 60477 USA
关键词
atypical; antipsychotic medications; psychosocial outcomes;
D O I
10.1016/S0920-9964(02)00379-1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This review examines the question-Do atypical antipsychotic medications improve psychosocial outcomes?-by examining studies that compared the effects of atypicals to conventional antipsychotics or to other atypical medications. The authors reviewed randomized clinical trials of atypical antipsychotic medication that included psychosocial variables as outcomes. Findings from 31 published studies on more than 12,000 individuals generally showed that atypical medications led to significant improvements in negative symptoms compared to conventional antipsychotics. Effects on global assessment of psychosocial functioning and on the quality of life were mixed with only about half the studies reporting significant improvements. Olanzapine yielded the best results on psychosocial functioning; remoxipride was found to yield few significant changes on these variables. This review provides evidence that some atypical antipsychotics may have direct effects on some of the psychosocial. disabilities that result from serious mental illness. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 36 条
[1]   Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo [J].
Arvanitis, LA ;
Miller, BG ;
Borison, RL ;
Pitts, WM ;
Sharif, ZA ;
Hamner, MB ;
Herz, MI ;
True, JE ;
Velligan, D ;
Knesevich, MA ;
Small, J ;
Steinbook, R ;
Hertzman, M ;
Keck, PE ;
Newcomer, JW ;
Grace, J ;
Rotrosen, J ;
Tandon, R ;
Dott, SG ;
Ferguson, JM ;
Addington, DEN ;
MacEwan, GW ;
Nair, VNP ;
Shriqui, CL ;
Williams, R ;
Daniel, DG ;
Shehi, GM ;
Patterson, WM ;
Merideth, CH .
BIOLOGICAL PSYCHIATRY, 1997, 42 (04) :233-246
[2]  
Awad AG, 1997, J PSYCHIATR NEUROSCI, V22, P244
[3]  
Beasley CM, 1997, J CLIN PSYCHIAT, V58, P7
[4]   Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study [J].
Bondolfi, G ;
Dufour, H ;
Patris, M ;
May, JP ;
Billeter, U ;
Eap, CB ;
Baumann, P .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (04) :499-504
[5]   A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia [J].
Copolov, DL ;
Link, CGG ;
Kowalcyk, B .
PSYCHOLOGICAL MEDICINE, 2000, 30 (01) :95-105
[6]   REHABILITATION RESEARCH METHODS FOR SCHIZOPHRENIA [J].
CORRIGAN, PW .
SCHIZOPHRENIA RESEARCH, 1989, 2 (06) :425-437
[7]   Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial [J].
Daniel, DG ;
Zimbroff, DL ;
Potkin, SG ;
Reeves, KR ;
Harrigan, EP ;
Lakshminarayanan, M .
NEUROPSYCHOPHARMACOLOGY, 1999, 20 (05) :491-505
[8]  
DENBOER JA, 1990, ACTA PSYCHIAT SCAND, V82, P108
[9]   REMOXIPRIDE AND HALOPERIDOL IN THE ACUTE PHASE OF SCHIZOPHRENIA - A DOUBLE-BLIND COMPARISON [J].
DEO, R ;
SONI, S ;
RASTOGI, SC ;
LEVINE, S ;
PLANT, I ;
EDWARDS, JG ;
MITCHELL, M ;
CHANAS, A .
ACTA PSYCHIATRICA SCANDINAVICA, 1990, 82 :120-124
[10]  
Essock SM, 1996, PSYCHOPHARMACOL BULL, V32, P683